Comparison of models for analyzing two-group, cross-sectional data with a Gaussian outcome subject to a detection limit

Statistical Methods in Medical Research

Volumn 25, Issue 6, 2016, Pages 2733-2749

  Wiegand, Ryan E ^a   Rose, Charles E ^a   Karon, John M ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Apex Systems Inc   (United States)

Author keywords

limit of detection; regression; statistical power

Indexed keywords

VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RALTEGRAVIR;

ARTICLE; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; DATA ANALYSIS SOFTWARE; EFFECT SIZE; HUMAN IMMUNODEFICIENCY VIRUS 1; INFERENTIAL STATISTICS; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MAXIMUM LIKELIHOOD METHOD; NONHUMAN; REGRESSION ANALYSIS; RNA ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MULTIVARIATE ANALYSIS; NORMAL DISTRIBUTION; PROBABILITY; PROCEDURES; SOFTWARE; STATISTICAL BIAS; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; BIAS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LIKELIHOOD FUNCTIONS; LIMIT OF DETECTION; MULTIVARIATE ANALYSIS; NORMAL DISTRIBUTION; PROBABILITY; RALTEGRAVIR POTASSIUM; RNA, VIRAL; SOFTWARE; VIRAL LOAD;

EID: 84995743973     PISSN: 09622802     EISSN: 14770334     Source Type: Journal    
DOI: 10.1177/0962280214531684     Document Type: Article

References (73)

1. Rifai N, Gillette MA, Parpia T,. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24: 971-983.
2. Looney SW, Hagan JL, Statistical methods for assessing biomarkers and analyzing biomarker data. In: Rao CR, Miller JP, Rao DC, (eds). Handbook of statistics 27: Epidemiology and medical statistics, Amsterdam: North Holland, 2008, pp. 109-147.
3. Attia S, Egger M, Müller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23: 1397-1404.
4. Marks G, Gardner LI, Craw J, et al. The spectrum of engagement in HIV care: Do more than 19% of HIV-infected persons in the US have undetectable viral load? Clin Infect Dis 2011; 53: 1168-1169.
5. Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults: Prevalence and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
6. Karon JM, Wiegand RE, van de Wijgert JH, et al. An evaluation of statistical methods for analyzing follow-up Gaussian laboratory data with a lower quantification limit. J Biopharm Stat 2015. to appear.
7. Armbruster DA, Tillman MD, Hubbs LM,. Limit of detection (LOD) limit of quantitation (LOQ)-Comparison of the empirical and the statistical, methods exemplified with Gc-Ms assays of abused drugs. Clin Chem 1994; 40: 1233-1238.
8. Chen YHJ, Fan C, Zhao J,. On methods to utilize HIV-RNA data measured by two different PCR assays. J Biopharm Stat 2008; 18: 724-736.
9. Wannemuehler KA, Lyles RH,. A unified model for covariate measurement error adjustment in an occupational health study while accounting for non-detectable exposures. Appl Stat 2005; 54: 259-271.
10. Jin Y, Hein MJ, Deddens JA, et al. Analysis of lognormally distributed exposure data with repeated measures and values below the limit of detection using SAS. Ann Occup Hygiene 2011; 55: 97-112.
11. Beal SL,. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
12. Moulton LH, Halsey NA,. A mixture model with detection limits for regression analyses of antibody response to vaccine. Biometrics 1995; 51: 1570-1578.
13. Moulton LH, Curriero FC, Barroso PF,. Mixture models for quantitative HIV RNA data. Stat Methods Med Res 2002; 11: 317-325.
14. Chu HT, Kensler TW, Muñoz A,. Assessing the effect of interventions in the context of mixture distributions with detection limits. Stat Med 2005; 24: 2053-2067.
15. Taylor DJ, Kupper LL, Rappaport SM, et al. A mixture model for occupational exposure mean testing with a limit of detection. Biometrics 2001; 57: 681-688.
16. Chu HT, Nie L, Kensler TW,. A Bayesian approach estimating treatment effects on biomarkers containing zeros with detection limits. Stat Med 2008; 27: 2497-2508.
17. Tooze JA, Grunwald GK, Jones RH,. Analysis of repeated measures data with clumping at zero. Stat Methods Med Res 2002; 11: 341-355.
18. Tobin J,. Estimation of relationships for limited dependent variables. Econometrica 1958; 26: 24-36.
19. Amemiya T,. Regression analysis when the dependent variable is truncated normal. Econometrica 1973; 41: 997-1016.
20. Hughes JP,. Mixed effects models with censored data with application to HIV RNA levels. Biometrics 1999; 55: 625-629.
21. Vaida F, Fitzgerald AP, DeGruttola V,. Efficient hybrid EM for linear and nonlinear mixed effects models with censored response. Comput Stat Data Anal 2007; 51: 5718-5730.
22. Vaida F, Liu L,. Fast implementation for normal mixed effects models with censored response. J Comput Graphical Stat 2009; 18: 797-817.
23. Jacqmin-Gadda H, Thiébaut R, Chêne G, et al. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 2000; 1: 355-368.
24. Lyles RH, Lyles CM, Taylor DJ,. Random regression models for human immunodeficiency virus ribonucleic acid data subject to left censoring and informative drop-outs. Appl Stat 2000; 49: 485-497.
25. Thiébaut R, Jacqmin-Gadda H,. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2004; 74: 255-260.
26. Lynn HS,. Maximum likelihood inference far left-censored HIV RNA data. Stat Med 2001; 20: 33-45.
27. Fu P, Hughes J, Zeng G, et al. A comparative investigation of methods for longitudinal data with limits of detection through a case study. Stat Methods Med Res 2012; pre-print: 1-14.
28. Duval V, Karlsson MO,. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharmaceut Res 2002; 19: 1835-1840.
29. Schafer JL, Graham JW,. Missing data: Our view of the state of the art. Psychol Methods 2002; 7: 147-177.
30. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-365.
31. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-1455.
32. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646-655.
33. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
34. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual transmission of HIV-1: Cross sectional and prospective cohort study. Brit Med J 2010; 340: c2205-c2205.
35. Altman DG,. Statistics in medical journals: Some recent trends. Stat Med 2000; 19: 3275-3289.
36. Deyi BA, Kosinski AS, Snapinn SM,. Power considerations when a continuous outcome variable is dichotomized. J Biopharmaceut Stat 1988; 8: 337-352.
37. Fedorov V, Mannino F, Zhang R,. Consequences of dichotomization. Pharmaceut Stat 2009; 8: 50-61.
38. Norris CM, Ghali WA, Saunders LD, et al. Ordinal regression model and the linear regression model were superior to the logistic regression models. J Clin Epidemiol 2006; 59: 448-456.
39. Farrington DP, Loeber R,. Some benefits of dichotomization in psychiatric and criminological research. Crim Behav Mental Health 2000; 10: 100-122.
40. Lewis JA,. In defence of the dichotomy. Pharmaceut Stat 2004; 3: 77-79.
41. Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004; 112: 1691-1696.
42. Jain RB, Caudill SP, Wang RY, et al. Evaluation of maximum likelihood procedures to estimate left censored observations. Anal Chem 2008; 80: 1124-1132.
43. Jain RB, Wang RY,. Limitations of maximum likelihood estimation procedures when a majority of the observations are below the limit of detection. Anal Chem 2008; 80: 4767-4772.
44. Chu H, Nie L,. A note on comparing exposure data to a regulatory limit in the presence of unexposed and a limit of detection. Biometric J 2005; 47: 880-887.
45. Wang HJ, Fygenson M,. Inference for censored quantile regression models in longitudinal studies. Ann Stat 2009; 37: 756-781.
46. García F, Niebla G, Romeu J, et al. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local virus replication. AIDS 1999; 13: 1491-1496.
47. Samson A, Lavielle M, Mentré F,. Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model. Comput Stat Data Anal 2006; 51: 1562-1574.
48. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21: 1723-1730.
49. Ghosh P, Branco MD, Chakraborty H,. Bivariate random effect model using skew-normal distribution with application to HIV-RNA. Stat Med 2007; 26: 1255-1267.
50. Paz-Bailey G, Sternberg M, Puren AJ, et al. Determinants of HIV type 1 shedding from genital ulcers among men in South Africa. Clin Infect Dis 2010; 50: 1060-1067.
51. Lyles RH, Williams JK, Chuachoowong R,. Correlating two viral load assays with known detection limits. Biometrics 2001; 57: 1238-1244.
52. Zuckerman RA, Whittington WL, Celum CL, et al. Higher concentration of HIV RNA in rectal mucosa secretions than in blood and seminal plasma, among men who have sex with men, independent of antiretroviral therapy. J Infect Dis 2004; 190: 156-161.
53. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 1999; 180: 93-98.
54. Buckley J, James I,. Linear regression with censored data. Biometrika 1979; 66: 429-436.
55. Vittinghoff E, McCulloch CE,. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007; 165: 710-718.
56. Hirji KF, Mehta CR, Patel NR,. Computing distributions for exact logistic regression. J Am Stat Assoc 1987; 82: 1110-1117.
57. Farewell VT,. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics 1982; 38: 1041-1046.
58. Lai TL, Ying Z,. Large sample theory of a modified Buckley-James estimator for regression analysis with censored data. Ann Stat 1991; 19: 1370-1402.
59. Harrell FE Jr. rms: Regression modeling strategies, 2013, http://CRAN.R-project.org/package=rms. R package version 3.6-3.
60. Chinn S,. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000; 19: 3127-3131.
61. Cohen J,. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988.
62. Lachenbruch PA,. Power and sample size requirements for two-part models. Stat Med 2001; 20: 1235-1238.
63. SAS Institute Inc. SAS/STAT® 9.2 user's guide, Cary, NC: SAS Institute Inc., 2008.
64. SAS Institute, Inc. Sample 25008: Generate data from a multivariate normal distribution, 2008, http://support.sas.com/kb/25/008.html.
65. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2012, http://www.R-project.org/.
66. Wickham H. ggplot2: Elegant graphics for data analysis. New York: Springer, 2009, http://had.co.nz/ggplot2/book.
67. Hsieh FY,. Sample size tables for logistic regression. Stat Med 1989; 8: 795-802.
68. Moorman AC, Holmberg SD, Marlowe SI, et al. Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: The HIV outpatient study (HOPS). Annals of Epidemiology 1999; 9(6): 349-357.
69. Rose CE, Martin SW, Wannemuehler KA, et al. On the use of zero-inflated and hurdle models for modeling vaccine adverse event count data. J Biopharmaceut Stat 2006; 16: 463-481.
70. Chu H, Nie L, Cole SR,. Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits. Stat Med 2006; 25: 2647-2657.
71. Nie L, Chu H, Cole SR,. A general approach for sample size and statistical power calculations assessing the effects of interventions using a mixture model in the presence of detection limits. Contemp Clin Trials 2006; 27: 483-491.
72. Rubin DB,. Multiple imputation for nonresponse in surveys, New York: Wiley, 1987.
73. Yu LM, Burton A, Rivero-Arias O,. Evaluation of software for multiple imputation of semi-continuous data. Stat Methods Med Res 2007; 16: 243-258.